Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1117MR)

This product GTTS-WQ1117MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1117MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6186MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ9910MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ5415MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ2411MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ3677MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ14348MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ13196MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15547MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW